Return to search results
Cangrelor
Kengreal (cangrelor) is an intravenous antiplatelet medication that works by inhibiting platelet aggregation to reduce the risk of blood clots during certain heart procedures. It's supplied as a 50 mg lyophilized powder for injection by Chiesi USA, Inc., and was approved by the FDA in 2015. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Kengreal (cangrelor) is an intravenous antiplatelet medication that works by inhibiting platelet aggregation to reduce the risk of blood clots during certain heart procedures. It's supplied as a 50 mg lyophilized powder for injection by Chiesi USA, Inc., and was approved by the FDA in 2015. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Cangrelor",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Cangrelor — ANDA 213551 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213551"
}
]
|
| identifier | ANDA213551 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-information",
"drug-safety",
"fda",
"prescription-drugs"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Cangrelor |
